Antidépresseurs sérotoninergiques et antalgiques opiacés : une association parfois « douloureuse » ! À propos d’un cas clinique

Reich, M.; Lefebvre-Kuntz, Danièle

doi:10.1016/j.encep.2009.03.010

Cited by 10 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although escitalopram oxalate has been considered as a one of the superior SSRIs, with favorable tolerability and less side effects in treatment of patients with depressive and anxiety disorders [ 15 , 16 ], a few adverse events of escitalopram oxalate should be noted, especially in the context of administration of escitalopram oxalate or escitalopram oxalate-containing regimens in cancer patients [ 47 , 48 , 49 ]. A previous case report indicated that a prostate adenocarcinoma patient receiving a major opiate analgesic exhibited serious serotoninergic symptoms such as diaphoresis, night sweating, tremors, diarrhea, and mydriasis after treatment with a small dose of escitalopram (5 mg/day) [ 47 ]. Notably, complete resolution of most serotonin syndromes was observed within 2 days after discontinuation of escitalopram oxalate [ 47 ], suggesting a risk of serotonin syndrome with escitalopram oxalate use.…”

Section: Discussionmentioning

confidence: 99%

“…A previous case report indicated that a prostate adenocarcinoma patient receiving a major opiate analgesic exhibited serious serotoninergic symptoms such as diaphoresis, night sweating, tremors, diarrhea, and mydriasis after treatment with a small dose of escitalopram (5 mg/day) [ 47 ]. Notably, complete resolution of most serotonin syndromes was observed within 2 days after discontinuation of escitalopram oxalate [ 47 ], suggesting a risk of serotonin syndrome with escitalopram oxalate use. Recently, a significantly higher QTc-interval, which is known as a risk marker of dangerous arrhythmias, was reported in breast cancer patients with concomitant use of tamoxifen and SSRIs, especially in the cases of paroxetine, escitalopram, and citalopram, indicating an adverse drug–drug interaction [ 48 ].…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, antidepressants, particularly escitalopram oxalate, are often used in liver cancer patients with depression comorbidity. Although escitalopram oxalate has been considered as a one of the superior SSRIs, with favorable tolerability and less side effects in treatment of patients with depressive and anxiety disorders [15,16], a few adverse events of escitalopram oxalate should be noted, especially in the context of administration of escitalopram oxalate or escitalopram oxalatecontaining regimens in cancer patients [47][48][49]. A previous case report indicated that a prostate adenocarcinoma patient receiving a major opiate analgesic exhibited serious serotoninergic symptoms such as diaphoresis, night sweating, tremors, diarrhea, and mydriasis after treatment with a small dose of escitalopram (5 mg/day) [47].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Combined Administration of Escitalopram Oxalate and Nivolumab Exhibits Synergistic Growth-Inhibitory Effects on Liver Cancer Cells through Inducing Apoptosis

Chen

Huang

et al. 2023

IJMS

View full text Add to dashboard Cite

Liver cancer is one of the most lethal malignant cancers worldwide. However, the therapeutic options for advanced liver cancers are limited and reveal scant efficacy. The current study investigated the effects of nivolumab (Niv) and escitalopram oxalate (Esc) in combination on proliferation of liver cancer cells both in vitro and in vivo. Significantly decreased viability of HepG2 cells that were treated with Esc or Niv was observed in a dose-dependent manner at 24 h, 48 h, and 72 h. Administration of Esc (50 μM) + Niv (20 μM), Esc (75 μM) + Niv (5 μM), and Esc (75 μM) + Niv (20 μM) over 24 h exhibited synergistic effects, inhibiting the survival of HepG2 cells. Additionally, treatment with Esc (50 μM) + Niv (1 μM), Esc (50 μM) + Niv (20 μM), and Esc (75 μM) + Niv (20 μM) over 48 h exhibited synergistic effects, inhibiting the survival of HepG2 cells. Finally, treatment with Esc (50 μM) + Niv (1 μM), Esc (50 μM) + Niv (20 μM), and Esc (75 μM) + Niv (20 μM) for 72 h exhibited synergistic effects, inhibiting HepG2 survival. Com-pared with controls, HepG2 cells treated with Esc (50 μM) + Niv (20 μM) exhibited significantly increased sub-G1 portion and annexin-V signals. In a xenograft animal study, Niv (6.66 mg/kg) + Esc (2.5 mg/kg) significantly suppressed the growth of xenograft HepG2 tumors in nude mice. This study reports for the first time the synergistic effects of combined administration of Niv and Esc for inhibiting HepG2 cell proliferation, which may provide an alternative option for liver cancer treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Combined Administration of Escitalopram Oxalate and Nivolumab Exhibits Synergistic Growth-Inhibitory Effects on Liver Cancer Cells through Inducing Apoptosis

Chen

Huang

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…[1111213141516] Rarely, SS may also be precipitated by concomitant use of SSRIs with metoclopramide,[171819] sibutramine, fenfluramine or dexfenfluramine, lithium, dihydroergotamine, sumatriptan; but risk is severe when SSRIs and MAOIs are combined. [4] Linezolid has been reported to induce SS as an interaction with almost every category of antidepressant medications like imipramine,[20] amitriptyline,[2122] fluoxetine,[2324] citalopram,[32526] escitalopram,[25] paroxetine,[27] sertraline,[28] L-tryptophan (precursor of serotonin),[17] mirtazapine,[3] trazodone,[26] buspirone,[29] venlafaxine,[263031] and duloxetine.…”

Section: Discussionmentioning

confidence: 99%

Linezolid-Induced Near-Fatal Serotonin Syndrome During Escitalopram Therapy: Case Report and Review of Literature

Kulkarni¹,

Kulkarni

2013

Indian Journal of Psychological Medicine

View full text Add to dashboard Cite

Linezolid is a synthetic antimicrobial agent of the oxazolidinone class with weak, nonspecific inhibitor of monoamine oxidase enzymes. Concomitant therapy with an adrenergic or serotonergic agent or consuming tyramine (>100 mg/day) may induce serotonin syndrome (SS). We present a case report of near-fatal adverse interaction between linezolid and escitalopram inducing SS in a 65-year-old woman with sepsis, under empirical antibiotic treatment. This report also summarizes the current relevant literature as identified via PubMed, EMBASE, and PsycINFO, supplemented with a manual search of cross references.

show abstract

“…Il en est théorique-ment de même avec les analgésiques opioïdes et dérivés tels que l'oxycodone (Oxycontin ® ) [46,94] et le fentanyl (Durogesic ® ) [3,90] ;…”

Section: Antidépresseurs Et Comorbiditésunclassified

Antidepressants in oncology: specificity’s and particularities

Reich

2010

Psycho Oncologie

Self Cite

View full text Add to dashboard Cite

Les antidépresseurs font partie de l'arsenal pharmacologique classique du traitement des états dépressifs et anxieux. Dans le champ de l'oncologie, outre la dépression, ils comportent d'autres indications potentielles telles que les bouffées vasomotrices induites par l'hormonothérapie ou certaines douleurs neuropathiques liées au cancer ou à ses traitements (chirurgicaux ou chimiothérapies). Certaines particularités propres à leur utilisation en oncologie, les interactions pharmacologiques ainsi que les modalités de leur prescription sont à connaître. Afin d'optimaliser l'action des antidépresseurs, leur usage sera le plus souvent fait en association avec un traitement psychothérapeutique adapté. Enfin, le risque carcinologique des antidépresseurs, au regard des données actuelles de la littérature, reste hypothé-tique et ne doit pas faire occulter leurs avantages lorsqu'ils sont prescrits de façon adéquate.Abstract Antidepressants are part of the classical pharmacological armament of depressive and anxiety disorders. In the oncologic field, besides depression, they might have others potential indications such as hot flushes induced by hormonotherapy or some neuropathic pain related to the cancer or its treatment (surgery or chemotherapy). Some specific particularities due to their use in oncology, the pharmacological interactions and the modalities of their prescription should be known. In order to increase the antidepressant action, their prescription will most of the time be done in association with an adapted psychotherapeutic intervention. Last, the antidepressant carcinologic risk, regarding the present literature data, remains hypothetical and must not conceal their advantages when they are adequately prescribed.

show abstract

Antidépresseurs sérotoninergiques et antalgiques opiacés : une association parfois « douloureuse » ! À propos d’un cas clinique

Cited by 10 publications

References 34 publications

Combined Administration of Escitalopram Oxalate and Nivolumab Exhibits Synergistic Growth-Inhibitory Effects on Liver Cancer Cells through Inducing Apoptosis

Combined Administration of Escitalopram Oxalate and Nivolumab Exhibits Synergistic Growth-Inhibitory Effects on Liver Cancer Cells through Inducing Apoptosis

Linezolid-Induced Near-Fatal Serotonin Syndrome During Escitalopram Therapy: Case Report and Review of Literature

Antidepressants in oncology: specificity’s and particularities

Contact Info

Product

Resources

About